Fig. 4 | Scientific Reports

Fig. 4

From: Pipeline for development of acylated peptide based CGRP receptor antagonist with extended half-life for migraine treatment

Fig. 4

(a) Plasma exposure and (b) plasma exposure normalised to peak plasma concentrations of hαCGRP8-37 analogues conjugated with C20DA-γGlu at position 14, 17, 19, 20 and 25 at 5 min, 1 h, 6 h and 24 h post dosing in male NMRI mice. Data point represent mean and range of n = 2, except for C20DA-γGlu protraction at position 17 where n = 1. T½ for each compound is presented in legends.

Back to article page